Analyzing the mechanism of Rap1 activation in platelets: Rap1 activation is related to the release reaction mediated through the collagen receptor GPVI

• Published in: Thrombosis research 2006, Vol.118 (4), p.509-521
• Main Authors: Jung, Stephanie M., Ohnuma, Masaaki, Watanabe, Naohide, Sonoda, Mamiko, Handa, Makoto, Moroi, Masaaki
• Format: Article
• Language: English
• Subjects: Androstadienes - pharmacology; Apyrase - pharmacology; Biological and medical sciences; Blood and lymphatic vessels; Blood coagulation. Blood cells; Blood Platelets - metabolism; Blood vessels and receptors; Cardiology. Vascular system; Collagen - metabolism; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous; Fundamental and applied biological sciences. Psychology; GPVI; Humans; Integrin activation; Integrin alpha2beta1 - antagonists & inhibitors; Integrin alpha2beta1 - metabolism; Medical sciences; Molecular and cellular biology; Phosphorylation; Platelet; Platelet Membrane Glycoproteins - metabolism; Platelets; Protein Kinase Inhibitors - pharmacology; Pyrimidines - pharmacology; Rap1; rap1 GTP-Binding Proteins - antagonists & inhibitors; rap1 GTP-Binding Proteins - metabolism; Release reaction; Tyrosine - metabolism; Vertebrates: cardiovascular system
• ISSN: 0049-3848; 1879-2472
• DOI: 10.1016/j.thromres.2005.11.002

The abundant Rap1 in platelets becomes activated when these cells are stimulated by various agonists, but its function has remained unknown. In view of this, we developed an assay to quantitatively measure activated Rap1 and used it to determine relationships between Rap1 activation and several platelet functions: integrin α 2β 1 activation, tyrosine phosphorylation, and the release reaction. We looked at how these processes are affected by the protein kinase C inhibitor BIMI, tyrosine kinase inhibitor PP2, PI 3-kinase inhibitor wortmannin, and ADP scavenger apyrase. In CRP (collagen related peptide)-activated platelets, all the inhibitors severely inhibited Rap1 activation, but had little effect on integrin α 2β 1 activation, indicating that the integrin activation mechanism is different from the Rap1 activation mechanism, at least in GPVI-dependent activation. With p85α-null mouse platelets, we demonstrated that Rap1 activation involves PI 3-kinase p85α-dependent tyrosine phosphorylation. All the inhibitors similarly decreased Rap1 activation and the serotonin release reaction, and the inhibition of Rap1 activation was not due to the lack of released ADP. Our results indicate that platelet Rap1 activation is closely related to the release reaction and not to integrin α 2β 1 activation in GPVI-mediated platelet activation.